Aging is a complex process triggered by multiple factors,characterized by the gradual decline of physiological and behavioral capabilities.Among various organs,the brain is particularly susceptible to aging effects.Brain aging not only leads to cognitive decline in the elderly but also increases the risk of neurodegen-erative diseases,resulting in reduced quality of life and increased social aging burdens.Therefore,it is essential to thoroughly investigate the mechanisms and biomarkers of both physiological and pathological brain aging to enable early prevention,monitoring,and intervention.Mitochondria play a crucial role in both physiological and pathological brain aging processes,making mitochondrial-related mechanisms and biomarkers key research directions in this field.This article reviews the main manifestations and mechanistic differences between physi-ological and pathological brain aging,summarizes mitochondrial mechanisms in brain aging,identifies mito-chondrial-associated biomarkers,and proposes health-promoting,mitochondria-targeting interventions.

Hepatocellular carcinoma （HCC） is a major cause of cancer-related death， and surgical resection remains an important method for radical treatment， but it is urgently needed to solve the problem of high postoperative recurrence rate. Neoadjuvant therapy can reduce the high recurrence rate after surgery， and there are little benefits from neoadjuvant therapy for HCC due to a lack of effective treatment methods in the past. At present， combination therapy based on immune checkpoint inhibitors has a relatively high response rate and has thus changed the treatment landscape for patients with advanced HCC. This urges investigators to reexamine the neoadjuvant treatment strategies for HCC， and it is expected that neoadjuvant therapy can provide new opportunities， reduce the postoperative recurrence rate， and improve the survival rate after treatment. This article discusses the current status and prospects of neoadjuvant therapy for HCC and related hot topics， so as to provide more ideas for exploring neoadjuvant therapy for HCC.